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Objective: To evaluate the efficacy and risks of complications of pulse dosing of topical 
5-fluorouracil (5-FU) in the treatment of corneal intraepithelial neoplasia (CIN), and conjunctival 
squamous cell carcinoma (SCC). 
Design: Prospective, noncomparative case series. 
Participants: Fifteen patients with histological evidence CIN or SCC of the conjunctiva and 
cornea were identified by tumor biopsy. 
Methods: All patients clinically evident of CIN, or SCC were evaluated, with maximum 
30 months of follow-up were treated with pulsed dosing of 1% 5-FU. Treatment cycles were 
defined as four times per day for 4 days using the medication followed by 30 days without 
medication. The number of initial treatment was six cycles. 
Results: The mean age of the 15 patients was 50.8 years (range 25–78 years). Excision biopsy 
proved seven cases as CIN, and eight cases as locally invasive SCC. All patients remained disease 
free with a mean follow-up of 14.53 months (range 6-30 months). Additional chemotherapy was 
given after the initial treatment cycles, only for one case. 5-FU caused mild temporary local 
irritation, but no long-term intraocular or extra ocular complications. 
Conclusions: Adjuvant 1% topical 5-FU appears to be effective in the prevention of recur-
rence of conjunctival or corneal CIN and SCC after excision biopsy. Our results indicate that 
at least six cycles of topical 1% 5-FU is required to prevent local recurrence in the long term. 
It is well-tolerated and an effective method of treatment. No complications that would preclude 
use of our dose regimen were noted.
Keywords: chemotherapy, fluorouracil, neoplasia, treatment cycles
Introduction
Conjunctival intraepithelial neoplasia (CIN) is a frequent conjunctival tumor, while 
squamous cell carcinoma is the most frequent malignant tumor of the conjunctiva.1–6 
Early manifestation is a small mass mimicking pterygium growing at or around the 
limbus, occurring in middle-aged patients.2–4
Following excision alone recurrences are frequent. Effective postsurgical recur-
rence prevention is therefore highly desirable. The primary treatment modality for this 
lesion is wide local excision and supplemental cryotherapy, with accurate histological 
assessment of the surgical margins.3–5 However, the recurrence rate is still high, even 
when surgical margins of primary excision are free from malignant cells.7 Moreover, 
recurrences may be multiple and their occurrence greatly increases the risk of local 
spread.8 Local irradiation is sometimes used in conjunction with repeated excision to 
treat conjunctival recurrences of squamous cell carcinoma.9–10 However, side effects 
limit the use of supplemental irradiation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Topical conjunctival chemotherapy with antineoplastic 
drugs has recently been proposed as a new approach in the 
treatment of conjunctival premalignant lesions, (primary 
acquired melanosis and conjunctival intraepithelial neopla-
sia) with promising results.11–21 β-irradiation,9 topical urea,10 
and immunotherapy,11 have been shown to reduce recurrence 
rates. Topical interferon-α-2b has also been proposed as a 
possible medical alternative to surgical excision of primary 
or recurrent intraepithelial neoplasia.12 Topical chemothera-
peutic agents, including topical mitomycin C (MMC), and 
5-fluorouracil (5-FU), have been shown to be effective in 
treating conjunctival and corneal intraepithelial neoplasia 
alone, or as an adjunct to surgical excision,1,13–19 Although 
topical 5-FU has been shown to be effective in treating CIN, 
we propose an alternative dosing regimen that is as effec-
tive, better tolerated, and has reduced adverse side effects as 
compared with previous reported dosing regimens.17–19
Patients and methods
In this study we took biopsies from the conjunctival and 
corneal masses followed by application of topical 5-FU to 
evaluate the efficacy, and prevention of recurrence of CIN 
and SCC. Seven patients with histological confirmed CIN, 
and eight patients with SCC were treated with 1% topical 
5-FU. In this study, we defined conjunctival intraepithelial 
neoplasia, as any degree of basal layers of epithelial dysplasia 
(ie, mild, moderate, and severe), including the full epithelial 
thickness involvement (carcinoma in situ) without any evi-
dence of invasion. Squamous cell carcinoma was defined as 
when there is invasion to the conjunctival stroma.
The clinical data included patient age, race, gender, 
eye involved, tumor extent, and initial management. At the 
time of examination, data collection included visual acuity, 
tumor location, conjunctival quadrant involved, and extent of 
involvement on the conjunctival and corneal surfaces, based 
on clinical and histopathological evidence. Tumor features of 
vascularity, nodularity, and leukoplakia were recorded. All 
patients were negative for HIV test as a precipitating factor 
especially in the young. The mean age of this group of patients 
was 50.8 years, ranging from 25 to 78 years. All patients were 
of Arabic origin. Three males and twelve females; the right and 
left eyes were involved in nine and six patients respectively.
Inclusion criteria included patients presenting with con-
junctival and corneal tumors, proved histopathologically as 
cases of CIN or SCC. Exclusion criteria included patients, 
with conjunctival or corneal tumors other than CIN or SCC. 
Patients with AIDS and xeroderma pigmentosum were 
excluded from the study.
At presentation, the tumor involved the limbus and cornea 
in all 15 eyes, forniceal conjunctiva in one eye, and no tarsal 
conjunctival involvement. Excision biopsy was obtained in 
all patients from the thickest portion of the tumor. Disease 
involvement varied from 2.5 to 9 clock hours of the limbus; 
1.5 to 8 mm of extension into clear cornea; and 9 mm of 
extension into the bulbar conjunctiva. In fourteen eyes, the 
bulbar conjunctiva was freely mobile. One patient whose 
lesion was firmly affixed to the underlying tissues (Table 1, 
patient 9) topical 5-FU was prescribed after surgical biopsy. 
5-fluorouracil (5-FU) was prepared by the resident to be 
given subconjunctivally using 25-gauge needle as 5 mg 
immediately at the end of the surgery.
Eight patients were affected by conjunctival squamous 
cell carcinoma (four recurrent cases), one case (Table 1, 
patient 7) recurrent after excision. Patients 10, 11 and 14 
had recurrence twice after surgery. Seven cases were diag-
nosed as CIN. All patients received pulse dose of 1% 5-FU 
eye drops. The topical chemotherapy was administered four 
times daily for 4 days for six treatment cycles with 30 days 
interval between the cycles.
Each patient had excision biopsy of the tumor when a 
diagnosis of conjunctival or corneal epithelial tumor was 
suspected. The 1% 5-FU therapeutic agent was prepared, and 
given by subconjunctival injection using 25-gauge needle as 
5 mg immediately at the end of the surgery. In fourteen eyes 
the bulbar conjunctiva was freely mobile. One patient the 
lesion was firmly affixed to the underlying tissues. Patching 
the eye was done for 24 hours postoperatively. In the first 
postoperative visit four patients had some necrotic tissues over 
the excised tumor. The necrotic tissue was removed using wet 
cotton bud with 1% 5-FU (prepared eye drops). This applica-
tion was repeated for two to three days. All patients used the 
prepared 1% 5-FU eye drops four times a day for four days 
then repeated at 30 day intervals for six cycles. The 1% 5-FU 
therapeutic agent was prepared using polyvinyl alcohol and 
povidone solution as the vehicle. The medication bottle was 
returned to the pharmacy after each cycle of use.
Patient report, Table 1, No.7; A 47-year-old white female 
was evaluated for a conjunctival lesion of her right eye after 
recurrence of the lesion. The lesion was diagnosed earlier 
as pterygium. Excision of the mass was done for the second 
time. Her visual acuity was 1/60 in the right eye and 6/18 
in the left eye without correction. The right eye showed a 
limbal mass involving approximately 270° of the corneo-
scleral limbus that extended 6 mm into the corneal surface. 
No preauricular or cervical lymphadenopathy was detected. 
Histological examination of multiple conjunctival biopsies Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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showed carcinoma in-situ. Five milligrams of 5-FU was given 
in the subconjunctival tissues after biopsy was taken. The 
patient was treated with 1% topical 5-FU four times daily 
for 4 days, for six treatment cycles. The necrotic tissue on 
first and second day postoperatively was removed by sterile 
wet cotton bud with prepared 1% 5-FU eye drops. There was 
clinically no evidence of recurrence for 21 months after the 
final treatment cycle. SPSS software (version 13; SPSS Inc., 
Chicago, IL) was used to analyze some data such as mean of 
the age, and the time of the follow-up of this study.
Patient report, Table 1 No.15, A 45-year-old white 
female was referred for application of 5-FU 1% eye drops 
for her recurrent conjunctival squamous cell carcinoma. 
Excision of the mass in another ophthalmic department 
was done three times, with rapid recurrence of the tumor; 
histopathology was diagnosed as squamous cell carcinoma 
of the conjunctiva. She received mitomycin C 0.02% as eye 
drops after the diagnosed four times for four days for two 
cycles. Recurrences of the tumor, for the fourth time, led 
her treating ophthalmologist to refer her to our department. 
We managed the case by the subconjunctival 5 mg of 5-FU 
for two days after removal of the tumor and confirming the 
diagnoses for the fifth time as squamous cell carcinoma of 
the conjunctiva. She received the regular treatment of 5-FU 
1% eye drops for six cycles. The patient was clinically free 
from the tumor after 18 months of follow up.
During treatment, symptomatic side effects of the medi-
cation were recorded by the patients in a daily diary. Ocular 
examination was performed daily in the first week, and then 
at 1, 2, 3, 4, 5, and 6 months following treatment, then twice 
yearly thereafter. Clinical examination (slit-lamp biomi-
croscopy and photography) and morphological evaluation 
of conjunctival cytological specimens were used to monitor 
the efficacy of local chemotherapy, side effects, and recur-
rences. During the last clinic visit the visual acuity, tumor 
status, globe status, and systemic status were assessed. The 
main outcome measures were tumor control and medication-
related toxicity. The presence or absence of clinically evident 
CIN, and SCC were evaluated after each treatment interval. 
Patients were also monitored for adverse reactions to the use 
of topical 5-FU.
Results
Ten patients were treated with 1% topical 5-FU for histologi-
cal confirmed as squamous cell carcinoma of the conjunctiva, 
cornea, or both. The other five patients’ histopathology was diag-
nosed as conjunctival and corneal intraepithelial neoplasia. The 
mean follow-up time was 14.53 months (range 6–30 months).
The results are summarized in Table 1, while all the 
tumors were responsive to topical 1% 5-FU treatment. Most 
of the patients had resolution of the tumor, after the initial 
series of treatments, and required no additional 5-FU after 
six cycles.
One of these patients (Table 1; patient 11) is still under 
treatment. She is going on the last cycle with regular follow 
up. The second patient (Table 1; patient 8) received the last 
cycle two months ago and has had regular follow up with no 
recurrence. The third patient (Table 1, patient 15) had three 
recurrences after simple excision. After the third excision 
she received MMC 0.02% eye drops two cycles four times 
per day for four days of treatments in another ophthalmic 
department, continued to have early recurrence of the dis-
ease despite treatment. In our department with many times 
of recurrence, we put her on topical 5-FU for six cycles at 
monthly intervals with resolution of the tumor. The patient 
has remained free of recurrence for 12 months after the 
last treatment cycle. Another, one very old female patient 
(Table 1, patient 9) with tumor fixed to the sclera had partial 
excision of the tumor in another ophthalmic department, 
and was diagnosed by histopathology as squamous cell 
carcinoma of the conjunctiva. She was referred for initial 
treatment of 5-FU. Recurrence occurred after 5 months of 
the final treatment. This patient was given second additional 
cycles of topical 1% 5-FU to eradicate the disease at monthly 
intervals for six cycles. The patient has remained tumor-free 
for the ten months of observation after the second series of 
treatment.
Figure 1A shows the appearance of recurrent bulky con-
junctival mass at presentation, with a chronic inflammatory 
infiltrate (Table 1, patient 7). The tumor involving 270° of 
the corneoscleral limbus was successfully treated without the 
appearance of limbal stem cell deficiency. The visual acuity 
at presentation was counting fingers at one meter, improved 
to 6/24 without correction after the eradication of the tumor. 
Histopathology confirmed the diagnosis as carcinoma in-situ 
of the conjunctiva. Figures 1B and 1C shows the appearance 
of the eye after three and five treatment cycles respectively. 
Although this patient received topical steroid to reduce 
the ocular irritation and inflammation associated with the 
use of chemotherapy, is now tumor free for 21 months of 
follow-up.
Figure 2A shows a dramatic response to 1% 5-FU 
(Table 1, patient 8). Histological analysis showed 
intraepithelial neoplasia of the conjunctiva, with severe 
dysplasia. Figure 2B shows the appearance of the eye after 
six treatment cycles.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 1A extensive carcinoma in-situ at the time of presentation, involving most 
of the bulbar conjuctiva, imparting a gelatinous appearance to the conjunctiva and 
camouflaging the conjuctival vessels.
Figure 1B Appearance of the eye 3 months after the initial treatment cycle with 
topical 5-FU.
Figure 1C Appearance of the eye 5 months after the initial treatment cycle with 
topical 5-FU.
Figure  2A  right  conjunctival  intraepithelial  neoplasia,  with  severe  dysplasia  at 
presentation.
Figure 3A shows differentiated squamous cell carcinoma 
of the conjunctiva that was proved by histopathology seen 
at presentation (Table 1, patient 14). Figure 3B shows 
the appearance of the tumor was completely eradicated by the 
treatment of 5-FU 1% at the seven months of follow up.
Discussion
The management of conjunctival and corneal CIN and SCC 
continues to evolve.21,24–26 Until recently, surgical excision 
and cryotherapy of the conjunctival mass combined with 
alcohol corneal epitheliectomy were the main treatment 
strategies.27 Because most of these tumors arise at or near the 
limbus, extensive surgical excision or cryotherapy risks the 
development of limbal stem cell deficiency. Complete surgi-
cal removal of these tumors would have been difficult and 
would have likely resulted in obvious ocular surface scarring, 
like tissue granulation, pseudopterygium and symblepharon. 
Also diplopia from tissue foreshortening, blepharoptosis and 
other complications that can result from the healing process 
were often bothersome to the patient. Furthermore, the pos-
sibility that during the surgical procedure, some tumor cells 
may be reimplanted and cause recurrence of a neoplastic 
process, cannot be excluded. Additionally, tumor recur-
rence of approximately 30% following surgical resection 
has been reported.28 These problems have stimulated clini-
cians to investigate alternative treatments. Chemotherapy Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 2B right eye appearance after 6 months of 5-FU.
Figure 3A Left eye, well diffentiated squamous cell carcinoma at presentation.
Figure 3B Left eye, appearance after four months treatment by 5-FU.
with topical 5-FU had some advantages over the surgical 
approach. It does not rely on histological identification of 
the lesion, and it eradicates the histological, nonvisible nest 
of neoplastic cells. Chemotherapy spares the surrounding 
normal tissue, which is usually excised around the lesion. 
No limbal stem cell deficiency noted in patients treated with 
topical chemotherapy alone. Furthermore, patients prefer 
treatment with application of the drops rather than surgery. 
On the other hand, the chemotherapeutic treatment is longer, 
requires close follow-up and compliant patients, and may 
cause adverse reactions.
Because of the high recurrence rate and technical dif-
ficulties associated with surgical excision, many methods of 
treatment for CIN have been investigated.29–39 β-Irradiation,29 
topical chemotherapy,31–43 and immunotherapy17,30 have 
been used as an adjunct or alone in treatment of CIN. De 
Keizer et al34 first described the use of topical 5-FU in 
the treatment of premalignant lesions of the cornea, conjunc-
tiva, and eyelid. Yeatts et al35–36 corroborated the effectiveness 
of 5-FU; subsequently, other investigators reported the use of 
MMC alone or as an adjunct to surgical excision in treatment 
of CIN.31–33,42 Current treatment regimens involve topical 
administration of 5-FU or MMC four times daily for 1 to 
2 weeks.30–34 One or more side effects are observed in almost 
all patients and include: conjunctival and corneal inflamma-
tion; corneal epithelial defects and the associated pain; and, 
eyelid skin erythema, irritation, and discomfort.
The role of topical 5-FU in the treatment regimen of CIN 
and SCC appears promising. Administering the 1% 5-FU 
four times daily but limiting the dose duration to 4 days with 
repeat cycles every 30 days for four to six cycles appears to 
be as efficacious as a longer dose period of 7 to 14 days, and 
without the adverse side effects.34–36 Thus, multiple treatment 
exposures may be required to expose all tumor cells to the 
chemotherapeutic agent during the time of their maximal 
susceptibility. The number of treatment cycles required to 
eradicate CIN is unknown.38
Topical chemotherapy is not recommended as a single or 
solitary treatment of invasive squamous cell carcinoma of the 
cornea and conjunctiva. The potential failure of penetration 
of a topical chemotherapeutic agent limits its role in invasive 
disease.36–37 However, topical therapy may play a useful role 
in reducing the tumor size and eliminating intraepithelial dis-
ease, thereby limiting the subsequent excision to the smaller 
invasive component.
Topical chemotherapy has several advantages when 
compared with the traditional surgical excision and 
cryotherapy.34,43 The potential advantages include: treatment 
of the entire ocular surface, thereby eliminating the need to 
ensure clear tissue margins, as is necessary with surgical 
excision; apparent targeting of the tumor cells, reducing 
the risk of limbal stem cell deficiency associated with more 
destructive therapies involving the limbus; simplicity of treat-
ment and reduced patient cost associated with avoidance of 
the surgical area; and reduced patient morbidity. Although 
the recurrence rate of CIN in patients treated with topical 
chemotherapy is unknown, treatment of the entire ocular Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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surface may theoretically reduce recurrent disease associated 
with focal destructive procedures.38
Toxicity to the lacrimal drainage apparatus was reported 
with topical 5-FU,40 but not observed in any patient in this 
study. Some patients developed skin irritation, but no experi-
ence of conjunctival injection, keratopathy, with our treatment 
regime. Some of our patients required additional treatment 
like dexamethasone eye drops to control the inflammatory 
reaction. One patient was given additional treatment cycle 
of 1% 5-FU due to early recurrence, and remained tumor 
free after ten months follow up. In such cases, other che-
motherapeutic drugs can be used instead of MMC.35–36,40 
Both topical interferon and topical 5-FU were reported as 
alternative treatments for MMC. Only one report indicated 
efficacy of topical interferon for CIN.35–36 A small number 
of CIN cases were successfully treated with topical 5-FU.40 
Larger series of cases with long-term follow-up and com-
parative studies are required to consider topical 5-FU as an 
alternative to MMC.
Maskin,40 investigating the presence of HPV in neoplastic 
and non-neoplastic disorders of the external eye, detected 
evidence of HPV by the polymerase chain reaction in 57% 
of patients with carcinoma in situ of the conjunctiva, 55% 
of patients with invasive squamous cell carcinoma, 35% of 
patients with scarred corneas, and in 32% of patients with 
normal conjunctival tissue obtained at cataract surgery.
The proper approach to presumed CIN lesions requires 
histological diagnosis by excisional biopsy for small lesions 
and incisional biopsy for large lesions before further treat-
ment is considered.21,41 Impression cytology, brush or scrap-
ing for histologic diagnosis of the conjunctival cells also may 
be useful. We believe that the general ophthalmologist, with 
limited clinical experience to intraepithelial lesions, should 
use one of the diagnostic measures before prescribing 5FU. 
However, an experienced expert in the field of cornea or 
ocular tumors who clinically diagnoses a small-size growing 
CIN with typical leukoplakia may use a topical chemotherapy 
based on clinical impression, particularly in patients who 
refuse any surgical approach, and those who can comply with 
the treatment and be easily monitored.
This study suggests that, treatment of corneal and con-
junctival intraepithelial neoplasia, and squamous cell carci-
noma with pulse doses of topical 1% 5-FU four times daily 
for 4 days, with repeat treatment cycles at monthly intervals 
for six cycles, is effective in treating CIN, and SCC, with 
no demonstrable side effects. Retreatment is required when 
the lesion recurs, and excisional biopsy should be done 
when the treatment fails. Long-term follow-up is required 
in these patients, as CIN lesions may recur years after the 
treatment.
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